Avanos Medical, Inc.
HealthcareNYSE:AVNS · New York Stock Exchange
-$0.02 today
Vol 0.31M · Avg 1.51M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $65.6M |
| Receivables | $103.0M |
| Inventory | $141.3M |
| Other Current | $15.1M |
| Total Current Assets | $325.0M |
| PP&E (Net) | $150.5M |
| Goodwill | $394.0M |
| Intangible Assets | $114.7M |
| Tax Assets | $33.0M |
| Other Non-current | $32.9M |
| Total Non-current Assets | $725.1M |
| Total Assets | $1.1B |
Analysis
Selected assets total $1.1B for Latest. The largest visible component is Goodwill at $394.0M, about 37.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $89.8M -16.6% | $107.7M +22.8% | $87.7M -31.3% | $127.7M +7.8% | $118.5M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $103.8M -21.8% | $132.8M -7.0% | $142.8M -14.9% | $167.9M +28.0% | $131.2M | $533.8M | $399.4M | -$1.7B |
| Inventory | $148.0M +6.6% | $138.8M -15.0% | $163.2M +23.4% | $132.3M -16.9% | $159.3M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $13.8M -2.1% | $14.1M -84.9% | $93.3M -52.4% | $196.2M | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $355.4M -9.7% | $393.4M -19.2% | $487.0M -22.0% | $624.1M +46.0% | $427.6M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $141.0M -2.6% | $144.8M +0.6% | $144.0M -1.4% | $146.1M -29.3% | $206.7M | $1.2B | $1.5B | $687.8M |
| Goodwill | $394.9M -13.3% | $455.6M -42.8% | $796.1M +4.7% | $760.3M -5.2% | $801.6M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $117.8M +4.9% | $112.3M -53.1% | $239.5M +2.3% | $234.2M +65.9% | $141.2M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $33.1M +32.9% | $24.9M +283.1% | $6.5M +41.3% | $4.6M -54.0% | $10.0M | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $31.5M +35.8% | $23.2M +20.2% | $19.3M +9.7% | $17.6M +6.7% | $16.5M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $718.3M -5.6% | $760.8M -36.9% | $1.2B +3.7% | $1.2B -1.1% | $1.2B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $1.1B -7.0% | $1.2B -31.8% | $1.7B -5.3% | $1.8B +11.4% | $1.6B | $13.3B | $11.9B | $10.6B |
| Account Payables | $55.5M +2.2% | $54.3M -3.6% | $56.3M -17.1% | $67.9M +20.4% | $56.4M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $10.2M +8.5% | $9.4M +9.3% | $8.6M +38.7% | $6.2M | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $18.0M +7.8% | $16.7M -21.2% | $21.2M +606.7% | $3.0M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $0 -100.0% | $73.3M -32.6% | $108.7M +1431.0% | $7.1M | $0 | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $165.2M -0.4% | $165.9M -29.3% | $234.6M +22.8% | $191.0M +37.2% | $139.2M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $90.3M -27.9% | $125.3M -21.4% | $159.4M -29.6% | $226.3M +74.1% | $130.0M | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $6.1M +10.9% | $5.5M -76.9% | $23.8M -6.3% | $25.4M +113.4% | $11.9M | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $13.5M +206.8% | $4.4M -56.0% | $10.0M -51.2% | $20.5M +125.3% | $9.1M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $130.3M -18.5% | $159.8M -27.9% | $221.5M -27.3% | $304.7M +57.2% | $193.8M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $295.5M -9.3% | $325.7M -28.6% | $456.1M -8.0% | $495.7M +48.9% | $333.0M | $14.7B | $3.7B | $9.6B |
| Common Stock | $500.0K +0.0% | $500.0K +0.0% | $500.0K +0.0% | $500.0K +0.0% | $500.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$779.9M -10.3% | -$707.0M -124.5% | -$314.9M -24.4% | -$253.1M +16.6% | -$303.6M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$32.0M +28.3% | -$44.6M -65.2% | -$27.0M +24.6% | -$35.8M -5.9% | -$33.8M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $778.2M -6.1% | $828.5M -33.0% | $1.2B -4.3% | $1.3B +1.6% | $1.3B | $9.1B | $7.7B | $3.3B |
| Total Debt | $129.1M -24.1% | $170.2M -18.6% | $209.1M -24.5% | $277.0M +47.7% | $187.5M | $724.2M | $410.6M | $399.4M |
| Net Debt | $39.3M -37.1% | $62.5M -48.5% | $121.4M -18.7% | $149.3M +116.4% | $69.0M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
CeriBell, Inc.
NASDAQ:CBLL
$700.80M
Bioventus Inc.
NASDAQ:BVS
$576.54M
Cytek Biosciences, Inc.
NASDAQ:CTKB
$511.40M
Varex Imaging Corporation
NASDAQ:VREX
$464.78M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Community Health Systems, Inc.
NYSE:CYH
$439.66M
Pacific Biosciences of California, Inc.
NASDAQ:PACB
$406.89M
ClearPoint Neuro, Inc.
NASDAQ:CLPT
$403.06M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Bicycle Therapeutics plc
NASDAQ:BCYC
$281.05M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does AVNS have?
Avanos Medical, Inc. (AVNS) reported $89.80M in cash and equivalents in fiscal 2025.
How much debt does AVNS carry?
Avanos Medical, Inc. (AVNS) reported $129.10M of total debt, with net debt of $39.30M.
Explore More
Continue the stock analysis
Jump to another research area for this company.